Overview

Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma.

Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability and determine the recommended phase 2/phase 3 dose of RAD regimen in PCNSL
Phase:
Phase 1
Details
Lead Sponsor:
National Health Research Institutes, Taiwan
Collaborators:
Chang Gung Memorial Hospital
China Medical University Hospital
National Cheng-Kung University Hospital
National Taiwan University Hospital
Treatments:
Acalabrutinib
Durvalumab
Rituximab